Jounce Therapeutics (JNCE) Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Jounce Therapeutics in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" JNCE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in JNCE, but not buy additional shares or sell existing shares.
View JNCE analyst ratings or view top-rated stocks.

4 brokers have issued 12-month target prices for Jounce Therapeutics' shares. Their JNCE share price forecasts range from $3.00 to $11.00. On average, they anticipate the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 219.1% from the stock's current price.
View analysts price targets for JNCE or view top-rated stocks among Wall Street analysts.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our JNCE earnings forecast.

Jounce Therapeutics, Inc. (NASDAQ:JNCE) posted its quarterly earnings results on Thursday, November, 4th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by $0.15. During the same period in the previous year, the firm posted ($0.73) earnings per share.

IQ Merger Arbitrage ETF holds 1,024,423 shares of JNCE stock, representing 0.35% of its portfolio.

45 employees have rated Jounce Therapeutics Chief Executive Officer Richard Murray Ph.D on Glassdoor.com. Richard Murray Ph.D has an approval rating of 97% among the company's employees. This puts Richard Murray Ph.D in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Jounce Therapeutics investors own include Exelixis (EXEL), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), CRISPR Therapeutics (CRSP), Novavax (NVAX), Mylan (MYL), Progenics Pharmaceuticals (PGNX), Adaptimmune Therapeutics (ADAP), Incyte (INCY) and Nektar Therapeutics (NKTR).

(JNCE) raised $76 million in an initial public offering on Friday, January 27th 2017. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.

Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE."

Jounce Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.84%), JPMorgan Chase & Co. (2.16%), BML Capital Management LLC (2.09%), State Street Corp (1.53%), Geode Capital Management LLC (1.46%) and Beryl Capital Management LLC (1.16%). Insiders that own company stock include Barbara Gayle Duncan, Elizabeth Trehu, Hugh M Cole, John Duncan Higgons, Kevin C Tang, Kimberlee C Drapkin, Richard /Ca/ Murray, Rock Ventures Ii LP Third and Rock Ventures Iii LP Third.
View institutional ownership trends.

One share of JNCE stock can currently be purchased for approximately $1.88.

Jounce Therapeutics (NASDAQ:JNCE) has a market capitalization of $98.94 million and generates $82 million in revenue each year. The company earns $-50,920,000.00 in net income (profit) each year or ($2.56) on an earnings per share basis.

The company employs 137 workers across the globe.

Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The official website for the company is www.jouncetx.com. The company can be reached via phone at (857) 259-3840 or via email at mdeon@jouncetx.com.